|
|
| |
|
Day 1 - Wednesday, October 15, 2008
|
| 8:00 AM - 12:00 PM |
Short Symposia 1:
Regulations & Policy in
Drug Development |
Short Symposia 2:
Stem Cells as Tools for
Drug Discovery
|
Short Symposia 3:
Imaging Technologies
|
| |
|
|
|
|
|
|
|
1:15 PM
|
Plenary Keynote Session Begins/Opening Remarks
|
| 1:30 PM |
|
|
David Nicholson, Ph.D.
Senior Vice President, Global Project Management
Schering Plough
|
|
|
| 2:15 PM |
|
|
John Doll
Commissioner of Patents
United States Patent & Trademark Office
|
|
|
| 3:00 PM |
Break
|
| 3:30 PM |
|
|
Ashraf Hanna
Vice President, Alliance Management & Portfolio Planning
Genentech
|
|
|
| |
|
| 4:15 PM |
Announcement of Awards For Winning Posters
|
| |
|
| 4:30 PM |
Opening Reception/Poster Session
|
| |
|
Day 2 - Thursday, October 16, 2008
|
|
|
Plenary Keynote Session (Cont'd)
|
| 8:00 AM |
|
|
Johan Luthman
Global Head Exploratory Medicine Neurology
MerckSerono International
|
|
|
| 8:45 AM |
|
|
Keith James, Ph.D.
Vice President & Site Head
Pfizer, La Jolla
|
|
|
| 9:30 AM |
Break
|
| |
|
|
|
|
|
|
|
|
6 Concurrent Tracks
|
Track
Titles |
Biological Therapeutics |
Translational Medicine |
Partnering, Licensing & Outsourcing |
Drug Design & Lead Discovery |
Emerging Targets & Therapeutics |
Pharmaco-kinetics & Pharmaco-dynamics |
| |
|
|
|
|
|
|
| 10:00 AM |
Session I:
Antibodies & Beyond |
Session I:
Target Identification & Validation |
Session I:
Tools for Successful Partnering |
Session I: Screening & Hit Identification |
Session I:
Oncology |
Session I:
Drug Delivery to the Brain |
| 11:00 AM |
Session II:
Immunogenicity & Humanization |
Session II:
Biomarkers: Impact & Implementation |
Session II:
Methods of Financing |
Session II:
Hit to Lead |
Session I (Cont'd):
Oncology |
Session II:
The Importance of PK in Drug Discovery & Development |
| 12:30 PM |
Lunch
|
| 2:00 PM |
Session III:
Novel Protein & Peptide Therapeutics |
Session III:
Predictive Safety & Toxicology |
Session III:
Panels – Licensing in Cancer & CNS, Infectious Dis. |
Session II (Cont'd):
Hit to Lead |
Session I (Cont'd): Oncology
|
Session III:
The Impact of Disease on Small & Large Molecule PK |
| 4:00 PM |
Break
|
| 4:30 PM |
Mini Session I:
Humanized Mice |
Mini Session II:
Proteomic Applications |
Mini Session III:
Preventing & Minimizing Drug Attrition |
| 6:00 PM |
DAY 2 CONCLUDES
|
| |
|
Day 3 - Friday, October 17, 2008
|
| 8:00 AM |
Mini Session IV:
Genetics & Genomics in Drug Discovery & Development |
Mini Session V:
In Silico Modeling of Biosystems
|
Mini Session VI:
Combination Therapeutics |
| 9:30 AM |
Break
|
|
|
6 Concurrent Tracks (Cont'd)
|
Track
Titles |
Biological Therapeutics |
Translational Medicine |
Partnering, Licensing & Outsourcing |
Drug Design & Lead Discovery |
Emerging Targets & Therapeutics |
Pharmaco-kinetics & Pharmaco-dynamics |
| |
|
|
|
|
|
|
| 10:00 AM |
Session IV:
Drug Delivery Technologies for Biologics |
Session IV:
Developing Predictive Preclinical Models |
Session IV: Alliance Management & Types of Partnerships |
Session III: Lead Optimization |
Session III & IV:
CNS Diseases; Inflammatory Pathways |
Session IV:
State of the Art Review: PK/PD Analysis & Modeling in Drug Development |
| 12:30 PM |
Lunch
|
| 1:30 AM |
Session V:
Modern Vaccine Development |
Session V:
Clinical Integration - From Bench to Bedside
|
Session V:
Outsourcing & Licensing |
Session III (Cont'd): Lead Optimization |
Session V:
Metabolic & Infectious Diseases
|
Session IV (Cont'd): State of the Art Review: PK/PD Analysis & Modeling in Drug Dev. |
| 4:00 PM |
CONFERENCE CONCLUDES
|
| |
|
|